Navigation Links
Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
Date:9/17/2007

ANN ARBOR, Mich., Sept. 17 /PRNewswire/ -- Terumo Heart, Inc. announced today that it had a successful European Launch Symposium at the European Association of Cardio-Thoracic Surgeons (EACTS) meeting in Geneva, Switzerland.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061027/DEF004LOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20070227/CLTU043LOGO )

A summary of the European Clinical Trial results for the DuraHeart(TM) Left Ventricular Assist System (LVAS) was presented by Dr. Aly El-Banayosy from the Heart Center Nordrhein-Westfalen in Bad Oeynhausen, Germany, followed by the presentation "The Emerging New Era of Mechanical Circulatory Support," by Dr. Eric Rose of Columbia University Medical Center in New York.

The symposium highlighted the DuraHeart device, as well as the BioValsalva Aortic Valved Conduit developed by Vascutek Ltd, a Terumo Company.

A summary of DuraHeart LVAS clinical results to-date (as of September 15, 2007):

* Patients enrolled = 33

* Median age (years) = 57 (29-73)

* Mean support duration (days) = 231194 (range: 17-803)

* Cumulative support duration = 7610 days (> 20 years)

* 7 patients (21%) supported > 1 year, and one supported > 2 years.

* 12 patients (36%) remain on support with a mean duration > 1 year (375

196 days)

* Kaplan Meier survival at 1 and 2 years was: 77% (all patients), 80% (<65

yrs), 90% (<60 yrs) and 100% (<50)

Chisato Nojiri, M.D., Ph.D., Chief Executive Officer for Terumo Heart, Inc., said; "We have had a number of significant milestones this year, most importantly receiving the CE Mark and a successful commercial launch in Europe."

The interest from surgeons at the EACTS has been extremely good. Dr. Nojiri commented, "We have been very pleased w
'/>"/>

SOURCE Terumo Heart, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
5. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
6. Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication
7. deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack
8. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
9. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
10. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015  MEI Pharma, Inc. (Nasdaq: MEIP ), ... novel therapies for cancer, today announced results for its ... - http://photos.prnewswire.com/prnh/20140805/133834 "Despite a ... pleased with how the Company is positioned entering fiscal ... President and Chief Executive Officer of MEI Pharma. "While ...
(Date:9/2/2015)... Sept. 2, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... its affiliate has entered into a definitive agreement under ... , Inc. (NASDAQ: SURG ) for $6.50 per ... payment, Synergetics stockholders will receive additional cash payments of ... are achieved following the closing.  The transaction is expected ...
(Date:9/2/2015)... , Sept. 2, 2015 Relmada Therapeutics, ... therapies for the treatment of chronic pain, announced today ... at both the FBR Second Annual Healthcare Conference and ... follows: FBR Second Annual Healthcare Conference ... Boston No presentation, investor meetings ...
Breaking Medicine Technology:MEI Pharma Reports Fiscal Year 2015 Results 2MEI Pharma Reports Fiscal Year 2015 Results 3MEI Pharma Reports Fiscal Year 2015 Results 4MEI Pharma Reports Fiscal Year 2015 Results 5MEI Pharma Reports Fiscal Year 2015 Results 6MEI Pharma Reports Fiscal Year 2015 Results 7Valeant Pharmaceuticals To Acquire Synergetics USA 2Valeant Pharmaceuticals To Acquire Synergetics USA 3Valeant Pharmaceuticals To Acquire Synergetics USA 4Valeant Pharmaceuticals To Acquire Synergetics USA 5Relmada Therapeutics to Participate in Two Upcoming Investor Conferences 2
... Texas, Feb. 16, 2012   Lexicon Pharmaceuticals, Inc. ... on discovering breakthrough treatments for human disease, will release ... on Wednesday, February 22, 2012 before the financial markets ... webcast to discuss clinical development progress and financial results ...
... that Medicare beneficiaries are not receiving necessary medical equipment ... Congress to adopt the Market Pricing Program (MPP) ... medical equipment and services, or durable medical equipment (DME). ... Medicaid Services (CMS), which implemented the bidding program in ...
Cached Medicine Technology:Lexicon to Report Fourth Quarter and Year End 2011 Financial Results on February 22, 2012 2American Association for Homecare Calls for Market-Based Alternative to Medicare's Bidding Program; Cites Lack of Access for Beneficiaries 2American Association for Homecare Calls for Market-Based Alternative to Medicare's Bidding Program; Cites Lack of Access for Beneficiaries 3American Association for Homecare Calls for Market-Based Alternative to Medicare's Bidding Program; Cites Lack of Access for Beneficiaries 4
(Date:9/2/2015)... Norcross, GA (PRWEB) , ... September 02, 2015 ... ... Aflac Cancer Center at Children's Healthcare of Atlanta to help support ... C.H.O.A. to discuss the upcoming WSB Radio Care-A-Thon , which is the ...
(Date:9/2/2015)... ... September 02, 2015 , ... Ericson is a noted speaker and ... HCPro and Associate Director of Education for the Association for Clinical Documentation Improvement Specialists ... for CDI Boot Camps. She serves as a CDI subject matter expert for a ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... largest and fastest-growing interim clinical staffing companies, has completed a recapitalization with ... , BPOC and Heritage Group each offer extensive expertise and ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... is taking action after seeing a significant increase in unlawful tactics used ... division has found many cases of OON ASCs encouraging members to have elective ...
(Date:9/2/2015)... , ... September 02, 2015 , ... Every year at ... others dread it. However, few are prepared to face the academic workload confronting them. ... Our schools haven’t prepared them since schools don’t teach students how to study. , ...
Breaking Medicine News(10 mins):Health News:DoMyOwnPestControl.com Goes Gold for Childhood Cancer Awareness Month 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3
... of Queensland believe that the conotoxins present in the ... from chronic pain//. This treatment could replace the conventional ... say that the toxin, snail uses to hunt its ... effects usually caused by other pain treatments. ...
... easily available to critically ill patients. The Food and Drug ... who are extremely ill to try out experimental drugs when ... FDA has announced that they will consider the prices that ... to needy individuals .They will also clarify the norms and ...
... by researchers from University of Sydney suggested that having ... problems in breastfeeding//. The study results were published in ... ,Researchers, who studied 1,300 women who gave birth ... have the anaesthetic are more likely to have problems ...
... for the American public. A decade after genetically altered ... remain ignorant and disinclined towards them. ,According to ... and Biotechnology, the last five years have seen little ... ,Says executive director of the survey’s sponsor, Michael ...
... conducted at the Auckland Aquatic Center in Henderson. //Six 12 ... at the West Wave Aquatic Centre on Dec 10. The ... be admitted in the hospital. ,Waitakere City Council ... concerned by what had occurred and investigations are continuing into ...
... effective as popular sports drinks and gels in maintaining ... endurance athletes who participated in a study by researchers ... study results were reported as a poster presentation at ... American College of Sports Medicine in San Diego last ...
Cached Medicine News:Health News:Gene-Altered Foods -Still Not Sure 2Health News:Sports-Formulated Jelly Beans Just as Effective as Sports Drinks 2
... Activins are polypeptide hormones which ... (TGF-) superfamily. The TGF- superfamily is ... factors which control many aspects of ... (1). Other members incude TGF-s, bone ...
... polypeptide hormones which belong to the ... TGF- superfamily is a large group ... many aspects of development, reproductive function ... incude TGF-s, bone morphogenetic proteins, growth ...
... known as bone Gla protein, is a ... a major component of the noncollagenous bone ... in bone, with a small amount produced ... [1]. During bone formation, newly synthesized osteocalcin ...
... Protein-1 (IGFBP-1) is a phosphoprotein, produced primarily ... modulates the bioactivity of IGF-I and IGF-II ... been completely defined, but the nature of ... involved in glucose regulation and IGF-mediated substrate ...
Medicine Products: